U.S., June 19 -- ClinicalTrials.gov registry received information related to the study (NCT07658105) titled 'Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVI' on June 14.
Brief Summary: Tumor recurrence is the leading cause of death and a major bottleneck for long-term survival in patients with hepatocellular carcinoma (HCC). Therefore, there is an urgent clinical need for effective postoperative adjuvant therapies to reduce postoperative recurrence and improve long-term survival, especially for HCC patients with high-risk factors. However, no standard adjuvant treatment regimen has been established so far, and domestic and international guidelines have not reached a consensus on relevant recommendations. It is generally rec...